| 中文别名 |
奥比沙星;1-环丙基-5,6,8-三氟-7-(顺式-3,5-二甲基哌嗪)-1,4-二氢-4-氧代喹啉-3-羧酸;奥比沙星 EP标准品;奥比沙星 USP标准品;奥比沙星 标准品;奥比沙星杂质混合 EP标准品;1-环丙基-5,6,8-三氟-7-(CIS-3,5-二甲基哌嗪)-1,4-二氢-4-氧-喹啉-3-羧酸;三氯苯咪唑;1-环丙基-5,6,8-三氟-1,4-二羟基-7-(顺式-3,5-二甲基-1-哌嗪基)-4-氧代-喹啉-3-羧酸;1-环丙基-5,6,8-三氟-1,4-二氢-7-(cis-3,5-二甲基-1-哌嗪基)-4-氧代喹啉-3-羧酸;奥比沙星溶液,100PPM;奥比沙星溶液, 1000PPM;奥比沙星标准品;奥比沙星溶液, 100UG/ML 甲醇溶液;奥比沙星溶液, 1000UG/ML 甲醇溶液 |
| 英文别名 |
Orbifloxacin;1-Cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxo-quinoline-3-carboxylic acid;CP-104354;1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid;Orbax;1-Cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic Acid;Obixacin;Marufloxacin;Orbifloxacin (350 mg);Orbifloxacin, Vetranal;Orbifloxacin Solution, 100ppm;Orbifloxacin solution,1000ppm;1-CYCLOPROPYL-6,7,8-TRIFLUORO-4-OXO-3-QUINOLINE CARBOXYLIC ACID;1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxo-quinoline-3-carboxylic acid;O-2950;AB00833179_04;Orbax [veterinary] (TN);1-cyclopropyl-7-((3R,5S)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;ORBIFLOXACIN (USP MONOGRAPH);113617-63-3;KS-5013;Pharmakon1600-01503711;A803076;NSC758614;660932TPY6;HMS3264M13;Orbifloxacin; 1-Cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;SMR000544203;SR-01000790054-2;Q7100015;Orbifloxacin impurity mixture;SCHEMBL125116;NSC-758614;Orbifloxacin, VETRANAL(TM), analytical standard;ORBIFLOXACIN [USP-RS];Orbax (veterinary);CHEMBL295433;1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-triluoro-4-oxoquinoline-3-carboxylic acid;BRD-K63001556-001-03-9;NCGC00160518-04;CP 104354;CCG-213832;HY-B0915;CHEBI:183823;NSC 758614;orbifloxacine;HMS2875G03;s4150;3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5,6,8-trifluoro-1,4-dihydro-4-oxo-, rel-;RKL10078;SR-01000790054;UNII-660932TPY6;CAS-113617-63-3;O0516;DivK1c_006462;orbifloxacino;1-CYCLOPROPYL-7-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)-5,6,8-TRIFLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID;NCGC00160518-01;1-cyclopropyl-5,6,8-trifluoro-7-(cis-3,5-dimethyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid;ORBIFLOXACIN [USP MONOGRAPH];MLS001216436;DTXCID5026201;Orbifloxacin, European Pharmacopoeia (EP) Reference Standard;QIPQASLPWJVQMH-DTORHVGOSA-N;orbifloxacinum;ORBIFLOXACIN [JAN];Orbifloxacin (USP/INN);SR-01000790054-3;ORBIFLOXACIN [MART.];1-Cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-4-ium-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylate;AB00833179_05;Tox21_111867;Orbifloxacin [USP:INN:BAN];NCGC00160518-02;BCP18829;ORBIFLOXACIN (USP-RS);D08299;MLS000766847;DB11443;1-cyclopropyl-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;CS-4384;ORBIFLOXACIN [USP IMPURITY];ORBIFLOXACIN [MI];Orbifloxacin, United States Pharmacopeia (USP) Reference Standard;Orbax Tablets;ORBIFLOXACIN (USP IMPURITY);SBI-0207085.P001;DTXSID7046201;Orbifloxacin [INN];Orbifloxacin, Antibiotic for Culture Media Use Only;1-Cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;1-Cyc... |
微信公众号
客服
